ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

Journal of Heart and Lung Transplantation

Volumn 35, Issue 2, 2016, Pages 213-221

  Gottlieb, Jens ^a   Zamora, Martin R ^b   Hodges, Tony ^c   Musk, A W ^d   Sommerwerk, Urte ^e   Dilling, Daniel ^f   Arcasoy, Selim ^g   DeVincenzo, John ^h   Karsten, Verena ⁱ   Shah, Shaily ⁱ   Bettencourt, Brian R ⁱ   Cehelsky, Jeffrey ⁱ   Nochur, Sara ⁱ   Gollob, Jared ⁱ   Vaishnaw, Akshay ⁱ   Simon, Amy R ⁱ   Glanville, Allan R ^j  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF COLORADO   (United States)

^c ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^d ROYAL PERTH HOSPITAL   (Australia)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ ALNYLAM PHARMACEUTICALS   (United States)

^j ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

bronchiolitis obliterans; community acquired infections; lung transplantation; respiratory syncytial virus; ribavirin; RNA interference

Indexed keywords

ASVASIRAN; IMMUNOGLOBULIN; PALIVIZUMAB; PLACEBO; RIBAVIRIN; SMALL INTERFERING RNA; STEROID; ANTIVIRUS AGENT;

ABNORMAL RESPIRATORY SOUND; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GRAFT RECIPIENT; HEMOPTYSIS; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; MULTICENTER STUDY; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHINORRHEA; RHONCHI; RISK REDUCTION; SURVIVAL; SYMPTOM; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS LOAD; WHEEZING; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; SYNDROME;

ADULT; ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RNA, SMALL INTERFERING; SYNDROME; TREATMENT OUTCOME;

EID: 84959920970     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.08.012     Document Type: Article

References (30)

1. E. Whimbey, R.E. Champlin, R.B. Couch, and et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients Clin Infect Dis 22 1996 778 782
2. E. Whimbey, J.A. Englund, and R.B. Couch Community respiratory virus infections in immunocompromised patients with cancer Am J Med 102 1997 10
3. W.P. Glezen, S.B. Greenberg, R.L. Atmar, and et al. Impact of respiratory virus infections on persons with chronic underlying conditions JAMA 283 2000 499
4. J. Gottlieb, T.F. Schulz, T. Welte, and et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study Transplantation 87 2009 1530
5. P.l. Hopkins, K. McNeil, F. Kermeen, and et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus Am J Respir Crit Care Med 178 2008 1
6. A.P. Khalifah, R.R. Hachem, M.M. Chakinala, and et al. Respiratory viral infections are a distinct risk for bronchiolitis oliterans syndrome and death Am J Respir Crit Care Med 170 2004 181
7. J.A. Belperio, S.S. Weigt, M.C. Fishbein, and et al. Chronic lung allograft rejection: mechanisms and therapy Proc Am Thorac Soc 6 2009 108
8. S.A. Yousem, S.R. Duncan, and B.P. Griffith Interstitial and airspace granulation tissue reactions in lung transplant recipients Am J Surg Pathol 16 1992 877
9. A. Boehler, and M. Estenne Post-transplant bronchiolitis obliterans Eur Respir J 6 2003 1007 1018
10. C.A. Finlen Copeland, L.D. Snyder, and et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients Am J Respir Crit Care Med 182 2010 784
11. J.L. Todd, and S.M. Palmer Bronchiolitis obliterans syndrome: the final frontier for lung transplantation Chest 140 2011 502
12. H. Reichenspurner, R.E. Girgis, R.C. Robbins, and et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation Ann Thorac Surg 62 1996 1467
13. A. Pelaez, G.M. Lyon, S.D. Force, and et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection J Heart Lung Transplant 28 2009 67
14. L.A. Danziger-Isakov, D. Arslan, S. Sweet, and et al. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative Pediatr Transplant 16 2012 638
15. V. Liu, G.S. Dhillon, and D. Weill A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients Transpl Infect Dis 12 2010 38
16. A.K. Vaishnaw, J. Gollob, C. Gamba-Vitalo, and et al. A status report on RNAi therapeutics Silence 1 2010 14
17. C.D. Novina, and P.A. Sharp The RNAi revolution Nature 430 2004 161
18. T. Coelho, D. Adams, A. Silva, and et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis N Engl J Med 369 2013 819
19. K. Fitzgerald, M. Frank-Kamenetsky, S. Shulga-Morskaya, and et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60
20. Zimmermann T, Karsten V, Harrop J, et al. Phase 1 First-in-Human Trial of ALN-TTRsc, a novel RNA interference therapeutic for the treatment of familial amyloidotic cardiomyopathy. In: Heart Failure Society of America Annual Scientific Meeting; 2013.
21. R. Alvarez, S. Elbashir, T. Borland, and et al. RNA Interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy Antimicrob Agents Chemother 53 2009 3952
22. J.L. DeVincenzo, R. Lambkin-Williams, and et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proc Natl Acad Sci 107 2010 1
23. M.R. Zamora, M. Budev, M. Rolfe, and et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus Am J Respir Crit Care Med 183 2011 531
24. K.C. Meyer, G. Raghu, G.M. Verleden, and et al. An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation Eur Respir J 44 2014 1479
25. D. Kumar, D. Erdman, S. Keshavjee, and et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant Am J Transplant 5 2005 2031
26. Dl Kumar, S. Husain, M.H. Chen, and et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients Transplantation 89 2010 1028
27. S.M. Palmer Jr, N.G. Henshaw, D.N. Howell, and et al. Community respiratory viral infection in adult lung transplant recipients Chest 113 1998 944
28. J.L. Billings, M.I. Hertz, K. Savik, and et al. Respiratory viruses and chronic rejection in lung transplant recipients J Heart Lung Transplant 21 2002 559
29. L. Li, R. Avery, M. Budev, and et al. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation J Heart Lung Transplant 31 2012 839
30. K.M. Vandervest, and M.R. Zamora Respiratory viral infections post-lung transplantation 2012 Springer Berlin 6